3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Carcinoma, Transitional Cell
3
Recurrence
2
Urinary Bladder Neoplasms
1
Solid Tumor, Miscellaneous
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Eosinophilia
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Imatinib Mesylate
12
Sunitinib
10
ripretinib
5
regorafenib
4
Blood Specimen Collection
3
envafolimab
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
Biopsy
2
trastuzumab deruxtecan
1
spartalizumab
1
ribociclib
1
pemigatinib
1
palbociclib
1
olverembatinib
1
nilotinib
1
guadecitabine
1
binimetinib
1
avelumab
1
avapritinib
1
atezolizumab
1
apatinib
1
Temozolomide
1
TAS-116
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
pemigatinib
×
1 year
×
Clear all
NCT07434843
2026-05-22
PEMIGIST
Dana-Farber Cancer Institute
Phase 2
Recruiting
24 enrolled